Vaxxinity to voluntarily delist, deregister its Class A common stock

Vaxxinity announced its intention to voluntarily delist from the Nasdaq Global Market and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended, and suspend its reporting obligations under Section 15(d) of the Exchange Act. On April 19, the company notified Nasdaq of its intent to voluntarily delist its Class A common stock from Nasdaq. The company currently anticipates that it will file with the SEC a Form 25 relating to the delisting and deregistration of its Class A common stock on or about April 29, 2024, and anticipates that the delisting and deregistration under Section 12(b) of its Class A common stock will then become effective on or about May 9, 2024. Following the delisting, any trading in the company’s Class A common stock would only occur in privately negotiated sales and potentially on an over-the-counter market. The company expects that its Class A common stock will initially be quoted on a market operated by OTC Markets Group so that a trading market may continue to exist for its Class A common stock for some period of time. There is no guarantee, however, that a broker will continue to make a market in the Class A common stock and that trading of the Class A common stock will continue on an OTC market or otherwise.